{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T07:22:32Z","timestamp":1770448952277,"version":"3.49.0"},"reference-count":88,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Gastroenterology & Hepatology"],"published-print":{"date-parts":[[2015,1,2]]},"DOI":"10.1586\/17474124.2014.953930","type":"journal-article","created":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T01:34:03Z","timestamp":1409535243000},"page":"9-20","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Asunaprevir-containing regimens for the treatment of hepatitis C virus infection"],"prefix":"10.1586","volume":"9","author":[{"given":"Sheng-Shun","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology and Hepatology, Taichung Veterans General Hospital,","place":["Taiwan"]},{"name":"Faculty of Medicine, School of Medicine, National Yang-Ming University,","place":["Taiwan"]},{"name":"Department of Nursing, Central Taiwan University of Science and Technology,","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[{"name":"Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine,","place":["Taiwan"]},{"name":"Hepatitis Research Center, National Taiwan University Hospital,","place":["Taiwan"]},{"name":"Department of Internal Medicine, National Taiwan University Hospital,","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,8,31]]},"reference":[{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.1999.6120139.x"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70216-4"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02540.x"},{"issue":"5","key":"e_1_3_3_8_1","first-page":"S3","article-title":"National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 \u2013","volume":"36","year":"2002","unstructured":"National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 \u2013. June 10-12, 2002. Hepatology 2002;36(5 Suppl 1):S3-20","journal-title":"Hepatology"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.1997.00120.x"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","unstructured":"Manns MP Rambusch EG. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol 1999;31(Suppl 1):39-42","DOI":"10.1016\/S0168-8278(99)80372-9"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.03.018"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26744"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.2001"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000087266"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-76-3-711"},{"issue":"9","key":"e_1_3_3_16_1","first-page":"2051","article-title":"Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa","volume":"25","author":"Liu CH","year":"2014","unstructured":"Liu CH, Kao JH. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine 2014;25(9):2051-67","journal-title":"Int J Nanomedicine"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.102558"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1086\/592579"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2005.01196.x"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22127"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009482"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014463"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12199"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26641"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.02.051"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.058"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.04.004"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.018"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70033-1"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.109309"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"e_1_3_3_37_1","unstructured":"Michael P Curry M Forns X et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Presented at 64th Annual Meeting of the American Association for the Study of Liver Diseases; 1 \u2013 5 November 2013; Washington DC USA"},{"key":"e_1_3_3_38_1","doi-asserted-by":"crossref","unstructured":"Cornpropst MT Denning JM Clemons D et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. Presented at 47th Annual Meeting of the European Association for the Study of the Liver; 18 \u2013 22 April 2012; Barcelona Spain","DOI":"10.1016\/S0168-8278(12)61113-1"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.775246"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X13515825"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208953"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8229.108182"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094542"},{"key":"e_1_3_3_44_1","unstructured":"Kim WR Congley S Roberts L et al. Impact of highly effective antiviral therapy on burden of hepatocellular carcinoma in hepatitis C cirrhosis. Presented at 48th Annual Meeting of the European Association for the Study of the Liver; 24 \u2013 28 April 2013; Amsterdam The Netherlands"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.03.012"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3182a502ba"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26300"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)60010-5"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12028"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.10.019"},{"key":"e_1_3_3_51_1","article-title":"The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor","author":"Eley T","year":"2014","unstructured":"Eley T, He B, Chang I, et al. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor. Antivir Ther 2014. [Epub ahead of print]","journal-title":"Antivir Ther"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S66731"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.921680"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2013.847089"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.892581"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S30946"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.929497"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.68.6.3753-3760.1994"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810950106"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2009.07.005"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1113329"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02550-08"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302048"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R110.125294"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81351-3"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5424.110"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2593"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.08.002"},{"key":"e_1_3_3_69_1","unstructured":"Reesink HW Zeuzem S Weegink CJ et al. Initial results of a phase 1b multiple dose study of VX-950 a hepatitis C virus protease inhibitor. Presented at 36th Digestive Disease Week; Chicago IL USA; 2005"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature02099"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm401840s"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm500297k"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01186-12"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05854-11"},{"key":"e_1_3_3_75_1","unstructured":"Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01030432"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2660"},{"key":"e_1_3_3_77_1","unstructured":"Study to determine the effectiveness of antiviral combination therapy to treat hepatitis C Virus (HCV) infected patients who have previously failed standard of care. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01012895"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104430"},{"key":"e_1_3_3_79_1","unstructured":"Lok A Gardiner D Hezode C et al. Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A inhibitor) and asunaprevir (ASV; NS3 inhibitor) with or without peginterferon alfa-2a\/ribavirin (PEG\/RBV). Presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases; 9 \u2013 12 November 2012; Boston MA USA"},{"key":"e_1_3_3_80_1","unstructured":"Study to determine the effectiveness and safety of a three drug antiviral combination therapy to treat hepatitis C virus (HCV) infected patients not previously treated with currently available medications. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01455090"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.057"},{"key":"e_1_3_3_82_1","unstructured":"An Anti-viral combination study with japanese hepatitis c infection (HCV) subject. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01051414"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24724"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.09.037"},{"key":"e_1_3_3_85_1","unstructured":"A Phase 3 Study in combination with BMS-790052 and BMS-650032 in Japanese hepatitis C virus (HCV) patients. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01497834"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27113"},{"key":"e_1_3_3_87_1","unstructured":"Phase III Hallmark DUAL: ASV+DCV (Nulls\/Partials intolerants\/ineligibles. Naives). Available from: http:\/\/clinicaltrials.gov\/show\/NCT01581203"},{"key":"e_1_3_3_88_1","unstructured":"Manns M Pol S Jacobson IM et al. All-oral dual therapy with daclatasvir and asunaprevir in patients with HCV genotype 1b infection: Phase 3 HALLMARK-DUAL study results. Presented at 49th Annual Meeting of the European Association for the Study of the Liver; 9 \u2013 13 April 2014; London UK"},{"key":"e_1_3_3_89_1","doi-asserted-by":"crossref","unstructured":"Kao JH Heo J Yoffe B et al. Efficacy and safety of daclatasvir in combination with asunaprevir in cirrhotic and non-cirrhotic patients with HCV genotype 1b: Results of the HALLMARK-DUAL study. Presented at 49th Annual Meeting of the European Association for the Study of the Liver; 9 \u2013 13 April 2014; London UK","DOI":"10.1016\/S0168-8278(14)61467-7"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00308-12"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26388"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.012"}],"container-title":["Expert Review of Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/17474124.2014.953930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:04:36Z","timestamp":1770390276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/17474124.2014.953930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,31]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1,2]]}},"alternative-id":["10.1586\/17474124.2014.953930"],"URL":"https:\/\/doi.org\/10.1586\/17474124.2014.953930","relation":{},"ISSN":["1747-4124","1747-4132"],"issn-type":[{"value":"1747-4124","type":"print"},{"value":"1747-4132","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierh20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierh20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-08-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}